anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sleep problem is very common symptom problems, so often rely on sedative-hypnotics drugs. However, long-term dependence on drugs may bring serious side effects. Therefore, the research topic is to explore the effectiveness of abdominal breathing on improving of sleep quality and physiological index (heart rate, respiration rate and blood pressure) among patients with insomnia. This study method adopts the research design of experimental randomized controlled trials. The persons receiving the intervention of abdominal breathing training are in the experimental group, while those who do not receive it are in the control group. The research is conducted with A and B groups. Group A is for those who take sedative and sleeping medicine, and Group B is for those who do not take sedative and sleeping medicine. Both groups A and B have experimental group and control group. The effectiveness assessment will use the Pittsburgh Quality Sleep Index (PSQI) and vital signs (heart rate, breathing and blood pressure). These assessments need to complete by both the experimental group and control group. This study uses the pre-test before the implementation of abdominal breathing training, and uses the post-test at week 4 and week 8 the end of abdominal breathing training. The experimental group will receive the abdominal breathing training for a total of 8 weeks. Abdominal breathing training is carry out in the sleep center of hospital (once every 1 week, and 15 minutes every time). When the persons are at home, they will receive self-training using the abdominal breathing training video (every day 10 minutes, can include every time during the day). Moreover, the persons need to complete the "abdominal breathing training log". Hopefully, this study may develop that does not use drugs, but improves sleep quality and physiological index through abdominal breathing.
As noted above ( CLINICAL PHARMACOLOGY), controlled trials have demonstrated that nitroglycerin ointment can effectively reduce exercise-related angina for up to 7 hours after a single application. Doses used in clinical trials have ranged from 1/2 inch (1.3 cm; 7.5 mg) to 2 inches (5.1 cm; 30 mg), typically applied to 36 square inches (232 square centimeters) of truncal skin. 

It is reasonable to believe that the rate and extent of nitroglycerin absorption from ointment may vary with the site and square measure of the skin over which a given dose of ointment is spread, but these relationships have not been adequately studied.

Controlled trials with other formulations of nitroglycerin have demonstrated that if plasma levels are maintained continuously, all anti-anginal efficacy is lost within 24 hours. This tolerance cannot be overcome by increasing the dose of nitroglycerin. As a result, any regimen of NITRO-BID® administration should include a daily nitrate-free interval. The minimum necessary length of such an interval has not been defined, but studies with other nitroglycerin formulations have shown that 10 to 12 hours is sufficient.

Thus, one appropriate dosing schedule for NITRO-BID® would begin with two daily 1/2- inch (7.5 mg) doses, one applied on rising in the morning and one applied six hours later. The dose could be doubled, and even doubled again, in patients tolerating this dose but failing to respond to it. The foilpac is intended as a unit dose package only and is equivalent to approximately 1 inch as squeezed from the tube. Use entire contents of foilpac to obtain full dose and discard immediately after use.

Each tube of ointment and each box of foilpacs is supplied with a pad of ruled, impermeable, paper applicators. These applicators allow ointment to be absorbed through a much smaller area of skin than that used in any of the reported clinical trials, and the significance of this difference is not known. To apply the ointment using one of the applicators, place the applicator on a flat surface, printed side down. Squeeze the necessary amount of ointment from the tube onto the applicator, place the applicator (ointment side down) on the desired area of the skin, and tape the applicator into place.
Acquired immune deficiency syndrome (AIDS) is a worldwide fatal infectious disease. In the past, patients usually die within six months to two years. With experiments for a plurality of years, a mixture for killing and completely curing AIDS is developed, wherein viruses in AIDS patient bodies can be completely killed after the patients take a dose of the mixture each day in 20-45 days, such that the AIDS can be completely cured so as to provide longevity. Characteristics of main symptoms treated by the mixture comprise that: symptoms of the patient at an early stage of virus infection like symptoms of a cold, and comprise high fever (body temperature is about 39 DEG or higher), muscular stiffness, fatigue, weakness, great and powerful rapid pulse; and then rash is generated over the body from extremities, hematuria and black feces are generated, genital blackens and decays, pain is generated on bones of the whole body, and various symptoms are generated. If the AIDS is cured, due to an easy recurrence characteristic of the AIDS, the patient takes a dose of the mixture each month in 2 years after the AIDS is cured so as to prevent recurrence and provide longevity. The formula of the mixture comprises 16 Chinese herbals comprising 30 g of Dongyetou, 30 g of rana temporaria, 30 g of purslane, 25 g of lobed kudzuvine root, and the like.
Each Cis/Gem treatment cycle will comprise cisplatin, dosed at 25 mg per square meter of body surface area, and gemcitabine, dosed at 1000 mg per square meter of body surface area. Each will be administered on Days 1 and 8 every 3 weeks.
Participants will use the default virtual reality headset welcome game, unrelated to mental health. It presents an interactive virtual environment, with various playful interfaces and instructions for use. The duration is approximately 15 minutes.
In this trial, a total of 50 subjects were recruited; the test vaccines were divided into 3 groups, low-dose vaccine groups, high-dose vaccine groups, and placebo groups. The first-stage randomized participants in the low-dose group (20 cases) and the placebo group (5 cases) were evaluated for 7 days. After the 7-day safety data was evaluated and agreed by the DSMB, the second-stage study was conducted. Into the high-dose group (20 cases) and placebo group (5 cases) subjects; follow-up to 30 days, after the safety assessment by the investigator and consent, then inoculate the second dose. Observation was performed for 1.0 hour after the second dose . The researchers conducted a safety evaluation and agreed to follow-up after discharge.

In this trial, all adverse events (AE), all AEs from 0-7 days, and all AEs from 8-30 days will be collected 30 minutes after each dose, and all AEs will be collected from the first dose to 30 days after the entire vaccination, and the first dose will be inoculated to the full course All serious adverse events (SAE) 6 months after vaccination.
AIMS: To determine whether a family history of unexplained heart failure (HF) in first-degree relatives (children or sibling) increases the rate of unexplained HF.
METHODS AND RESULTS: Using Danish nationwide registry data (1978-2017), we identified patients (probands) diagnosed with first unexplained HF (HF without any known comorbidities) in Denmark, and their first-degree relatives. All first-degree relatives were followed from the HF date of the proband and until an event of unexplained HF, exclusion diagnosis, death, emigration, or study end, whichever occurred first. Using the general population as a reference, we calculated adjusted standardized incidence ratios (SIR) of unexplained HF in the three groups of relatives using Poisson regression models. We identified 55,110 first-degree relatives to individuals previously diagnosed with unexplained HF. Having a family history was associated with a significantly increased unexplained HF rate of 2.59 (95%CI 2.29-2.93). The estimate was higher among siblings (SIR 6.67 [95%CI 4.69-9.48]). Noteworthy, the rate of HF increased for all first-degree relatives when the proband was diagnosed with HF in a young age (≤50 years, SIR of 7.23 [95%CI 5.40-9.68]) and having >1 proband (SIR of 5.28 [95%CI 2.75-10.14]). The highest estimate of HF was observed if the proband was ≤40 years at diagnosis (13.17 [95%CI 8.90-19.49].
CONCLUSION: A family history of unexplained HF was associated with a two-fold increased rate of unexplained HF among first-degree relatives. The relative rate was increased when the proband was diagnosed at a young age. These data suggest that screening families of unexplained HF with onset below 50 years is indicated.
A system and techniques are provided for suggesting a surgery plan and a surgical instrument selection. In some embodiments, the system may be configured to receive a set of inputs for a surgical procedure for a patient. Subsequently, the system may determine one or more potential plans for the surgical procedure based at least in part on the set of inputs and, in some implementations, a machine learning model. The system may then receive a selection of a plan from the one or more potential plans and determine a plurality of surgical instruments corresponding to the plan from the selection. Accordingly, the system may then be configured to provide an output that indicates the plurality of surgical instruments to load in a surgical tray. In some embodiments, the system may be configured to load the plurality of surgical instruments into the surgical tray.
The incidence of chronic graft versus host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) was 30%-70%, Which extremely limited the quality of life and the survival of patients after allo-HSCT. Lung is one of the target organs in cGVHD after allo-HSCT. Bronchiolitis obliterans syndrome (BOS) after allo-HSCT was a clinical syndrome characterized by persistent airflow restriction which is the result of lung cGVHD. BOS is one of the main causes of late mortality after allo-HSCT, severely restricting the daily activities and respiratory function of patients. It limits the quality of life and increased the non-relapse mortality (NRM) after allo-HSCT. Currently, the first-line treatment for BOS is FAM ( oral fluticasone, azithromycin and montelukast). However, more than 50% of patients develop as steroids resistant (SR)-BOS, and SR-BOS has a poor prognosis and irreversible impaired lung function. Ruxolitinib is an effective drug in the treatment of SR-cGVHD. This is a phase Ⅱ prospective clinical study to explore the efficacy and safety of ruxolitinib as a first-line treatment for newly diagnosed BOS after allo-HSCT.
Patients undergo a bowel management program comprising a medical management pathway (fiber, loperamide hydrochloride, pelvic floor physical therapy) in combination with RRE treatment for 1 year. Patients use the RRE system to self administer an individualized enema regimen via the rectum. Patients may undergo abdominal film x-rays throughout the trial.
The Aerobic Group will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
In the LBP study, patients 18 years of age or older with chronic low back pain and a baseline pain score of ≥5 on an 11-point numerical rating scale (NRS), ranging from 0 to 10 were enrolled and randomized to 1 of 3 treatments: NUCYNTA ER, active-control (an extended-release Schedule II opioid analgesic), or placebo.

Patients randomized to NUCYNTA ER initiated therapy with a dose of 50 mg twice daily for three days. After three days, the dose was increased to 100 mg twice daily. Subsequent titration was allowed over a 3-week titration period to a dose up to 250 mg twice daily, followed by a 12-week maintenance period. There were 981 patients randomized. The mean age of the study population was 50 (range 18 to 89) years; the mean baseline pain intensity score was 8 (SD 1). Approximately half of the patients were opioid-naïve (had not taken opioids during the three months prior to the screening visit).

The number of patients completing the study was 51% in the placebo group, 54% in the NUCYNTA ER group and 43% in the active-control group. Lack of efficacy was the most common reason for discontinuation among placebo-treated patients (21%), whereas adverse events were the most common reason for discontinuation among the active treatment groups (17% and 32% for NUCYNTA ER and active-control, respectively).

After 15 weeks of treatment, patients taking NUCYNTA ER had a significantly greater pain reduction compared to placebo. The proportion of patients with various degrees of improvement is shown in Figure 1. The figure is cumulative, such that patients, whose change from baseline is, for example 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned 0% improvement.
The invention relates to a natural medicine for treating senile constipation and a preparation thereof. The natural medicine provided by the invention is characterized by being prepared from a raw material of Sauropus changianus S.Y.Hu (leaves of Euphorbia Sauropus changianus or leaves of Sauropus rostratus Miq. and Sauropus spatula folius Beille). The invention provides the natural medicine for treating senile constipation and the preparation thereof. The preparation method is characterized in that an extract product obtained from the raw material of Sauropus changianus S.Y.Hu and a separated part or monomer are used to prepare the medicinal preparation according to a traditional processing method or modern means. The preparation is a dosage form such as tablet, capsule and the like in the modern pharmacy. By the use of the preparation provided by the invention, the disadvantage that senile constipation is more severe and leads to other symptoms after taking a drug for treating senile constipation and having diarrhoea is overcome. The advantages of the preparation are as follows: 1, the preparation is prepared according to characteristics of the aged that they are weak and are not resistant to disease attack; 2, the raw material is convenient to collect; and 3, the drug is cheap and has a good curative effect.
PURPOSE: To estimate time spent in various cardiovascular disease (CVD) and cancer states, according to self-reported walking pace.
METHODS: In total, 391,744 UK Biobank participants were included (median age = 57 years; 54.7% women). Data were collected 2006-2010, with follow-up collected in 2021. Usual walking pace was self-defined as slow, steady, average, or brisk. Multistate modeling determined the transition rate and mean sojourn time in and across three different states (healthy, CVD or cancer, and death) upon a time horizon of 10 years.
RESULTS: The mean sojourn time in the healthy state was longer, while that in the CVD or cancer state was shorter in individuals reporting an average or brisk walking pace (vs. slow). A 75-year-old woman reporting a brisk walking pace spent, on average, 8.4 years of the next 10 years in a healthy state; an additional 8.0 (95% CI: 7.3, 8.7) months longer than a 75-year-old woman reporting a slow walking pace. This corresponded to 4.3 (3.7, 4.9) fewer months living with CVD or cancer. Similar results were seen in men.
CONCLUSIONS: Adults reporting an average or brisk walking pace at baseline displayed a lower transition to disease development and a greater proportion of life lived without CVD or cancer.
AVAILABILITY OF DATA AND MATERIALS: Research was conducted using the UK Biobank resource under Application #33266. The UK Biobank resource can be accessed by researchers on application. Variables derived for this study have been returned to the UK Biobank for future applicants to request. No additional data are available.
Data regarding the use of FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in acute lymphoblastic leukaemia (ALL) are lacking. We identified 14 patients with FLT3- or IDH1/2-mutated ALL. Three early T-cell precursor-ALL patients received FLT3 or IDH2 inhibitors. Patient 1 maintains a complete remission (CR) with enasidenib after intolerance to chemotherapy. Patient 2 maintained a CR for 27 months after treatment with enasidenib for relapsed disease. Patient 3 was treated with venetoclax and gilteritinib at the time of relapse and maintained a CR with gilteritinib for 8 months. These cases suggest that FLT3 and IDH inhibitors could represent a viable therapeutic option for ALL patients with these mutations.
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to ophthalmology. For the surgical treatment of patients with macular edema complicated by the epiretinal membrane in diabetes mellitus, local posterior vitrectomy is performed with removal of the posterior hyaloid membrane, along with tamponade of the vitreal cavity with air and the introduction of an anti-vasoproliferative preparation. At the preoperative stage, microperimetry of the macular zone is conducted within radius of 12° from the point of fixation of the gaze. Surgical intervention is carried out using 27G technology, staining and removing the posterior hyaloid, epiretinal and internal limiting membrane (ILM) under intraoperative OCT control. ILM peeling is performed circularly, starting from the place with the lowest photosensitivity according to microperimetry, while performing ILM separation over 2–3 hour meridians with a movement directed along an arc of an imaginary circle centered in foveola, the ILM isolated along the arc is intercepted and further separation thereof with a circular motion is carried out. When an intraoperative OCT is detected in the projection of the fovea-hyporeflective formation with a diameter of more than 200 mcm, ILM peeling is completed at the site of the onset of the cyst.EFFECT: method ensures the safe elimination of traction effects and contributes to the creation of favorable conditions for resorption of edema by the method of drug accumulation in the central zone of the retina.1 cl, 2 ex
Some recent publications have used the term "vagal-adrenal axis" to account for mechanisms involved in the regulation of inflammation by electroacupuncture. This concept proposes that efferent parasympathetic nerve fibers in the vagus directly innervate the adrenal glands to influence catecholamine secretion. Here, we discuss evidence for anatomical and functional links between the vagi and adrenal glands that may be relevant in the context of inflammation and its neural control by factors, including acupuncture. First, we find that evidence for any direct vagal parasympathetic efferent innervation of the adrenal glands is weak and likely artifactual. Second, we find good evidence that vagal afferent fibers directly innervate the adrenal gland, although their function is uncertain. Third, we highlight a wealth of evidence for indirect pathways, whereby vagal afferent signals act via the central nervous system to modify adrenal-dependent anti-inflammatory responses. Vagal afferents, not efferents, are thus the likely key to these phenomena.
This review provides practical recommendations for dental practitioners in dealing with oral lesions associated with sexually transmitted diseases (STDs), offering clinically relevant insights to increase the awareness of these diseases in the mainstream of everyday practice. STDs are acquired through unprotected vaginal, anal or oral sex and are caused by more than 30 different types of bacteria, viruses and protozoa. Saliva, precum, semen, vaginal secretions and menstrual blood could be likely vehicles of infections and defensive barriers to infection by pathogenic microbes could be represented via intact mucosal membrane, the diluent function of saliva, and the antimicrobial action of salivary enzymes that collectively contribute to oral health and protection. STD, can directly and indirectly affect mucous membranes, manifesting with characteristic diagnostic signs and lesions. Given their potential oral manifestations, dental professionals need a comprehensive understanding of STD. The findings of this review lay a foundation for comprehending several STDs, emphasizing the importance of physicians as well dental practitioners being open to discussing sexuality issues with patients and providing appropriate therapeutic interventions.
This study will examine how two thyroid preparations, levothyroxine (T4) and liothyronine (T3), affect subcutaneous adipose tissue in normal subjects. Thyroid hormone plays an important role in the maintenance of energy metabolism. Specifically, hyperthyroidism is associated with weight loss via an increase in metabolic rate and lipolysis. While this phenomenon has been studied in vitro quite extensively, very little information is available on the local action of thyroid hormone on adipose tissue in vivo and, in particular, at the present no information is available on the role of peripheral conversion of thyroid hormone in subcutaneous adipose tissue. We thus propose to study the local action of thyroid hormones on adipose tissue using microdialysis, a minimally invasive technique that allows the serial determination of components of the extracellular fluid. The measurement of glycerol after correction for changes in blood flow will be used to evaluate the effects of the thyroid hormones on local lipolysis.

Healthy volunteers 18 years of age and older may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood tests. Subjects with hyperlipidemia, impaired glucose tolerance or diabetes and thyroid disease are not eligible for the participation in this study. Qualifying study participants undergo subcutaneous fat tissue microdialysis to assess the effects of T3 and T4 on the activity of fat tissue. The medications isoproterenol and T3 or T4 are injected in fat tissue under the skin of the abdomen, and fluid samples are collected from the area over a 6-12 hour period using the same small needle. Glycerol is then measured to study how the thyroid hormones affect fat metabolism. During this procedure a 10% glucose solution is infused through the catheter in the arm to limit lipolysis due to fasting. Four different sets of experiments are performed with different thyroid hormone doses and/or durations.

These experiments will provide new information on the role of thyroid hormone in the regulation of adipose tissue metabolism and will help in identifying new treatments for the management of obesity.
Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Anode on the primary motor area (M1) of dominant hemisphere and Cathode on the supraorbital area of non-dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.